Are you Dr. Kurtoglu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
10 Center Dr
Bldg 10 Room 12n226
Bethesda, MD 20892Phone+1 301-496-4916
Summary
- Dr. Metin Kurtoglu, MD is an internist in Bethesda, Maryland. He is currently licensed to practice medicine in District of Columbia and Florida.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
University of Miami/Jackson Health SystemResidency, Internal Medicine, 2010 - 2013
Istanbul University FomClass of 2002
Certifications & Licensure
DC State Medical License 2013 - 2014
FL State Medical License Active through 2014
Clinical Trials
- Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma Start of enrollment: 2018 Feb 26
Publications & Presentations
PubMed
- 54 citationsSafety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-rand...Volkan Granit, Michael Benatar, Metin Kurtoglu, Miloš D Miljković, Nizar Chahin
The Lancet. Neurology. 2023-07-01 - 58 citationsPreclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.Liang Lin, Shih-Feng Cho, Lijie Xing, Kenneth Wen, Yuyin Li
Leukemia. 2021-03-01 - 39 citationsGlobal variability of the human IgG glycome.Jerko Štambuk, Natali Nakić, Frano Vučković, Maja Pučić-Baković, Genadij Razdorov
Aging. 2020-08-12
Press Mentions
Maryland Stem Cell Research Commission Announces over $6 Million in Awards to Accelerate CuresMay 9th, 2021
A More Targeted CAR-T Cell-Based Therapy for Myasthenia Gravis Moves into Clinical Trial with University of FloridaNovember 7th, 2019
Cartesian Initiates CAR-T Clinical Trial in Myasthenia GravisNovember 5th, 2019
